Skip to main content
. Author manuscript; available in PMC: 2013 Nov 12.
Published in final edited form as: Chemotherapy. 2012 Nov 12;58(4):321–329. doi: 10.1159/000343165

Table 4.

Summary of Efficacy of Patients on Level 3 Dosages

Endpoint Number (Percent)
Response at two cycles (RECIST criteria)
Complete Response 0 (0)
Partial Response 0 (0)
Stable Disease 7 (64)
Progressive Disease 4 (36)
Time to Progression
Median (months) 2.8
95% CI (2.0–3.7)
Overall Survival
Median (months) 11.7
95% CI (5.9–27.0)
Progression-Free Survival
Median (months) 2.83
95% CI (1.3–5.2)